These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 446131)

  • 41. Controlled therapeutic trial with the combination rifampicin-isoniazid given for six months to previously untreated patients with pulmonary tuberculosis.
    Dubra F
    Bull Int Union Tuberc; 1972 Feb; 47():37-40. PubMed ID: 4562016
    [No Abstract]   [Full Text] [Related]  

  • 42. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report.
    Teo SK
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):126-32. PubMed ID: 10091877
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Short-course chemotherapy for tuberculosis with largely twice weekly isoniazid-rifampin.
    Moulding TS
    Chest; 1980 Mar; 77(3):453-4. PubMed ID: 7357956
    [No Abstract]   [Full Text] [Related]  

  • 44. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Rifampicin in the treatment of active pulmonary tuberculosis. Controlled trial of isoniazid-rifampicin-thiocarlide versus isoniazid-streptomycin-thiocarlide in untreated tuberculosis. Treatment of relapses with the combination rifampicin-ethambutol-thiocarlide].
    Chioléro R
    Schweiz Med Wochenschr; 1974 Mar; 104(10):356-64. PubMed ID: 4206521
    [No Abstract]   [Full Text] [Related]  

  • 47. Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    Am Rev Respir Dis; 1985 Aug; 132(2):374-8. PubMed ID: 2862820
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Short-course (6-month) cooperative tuberculosis study in Poland: results 30 months after completion of treatment.
    Zierski M; Bek E; Long MW; Snider DE
    Am Rev Respir Dis; 1981 Sep; 124(3):249-51. PubMed ID: 7283257
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Evaluation of the streptomycin twice weekly with INH and RFP for initial therapy of pulmonary tuberculosis].
    Toyota E; Suzuki T; Tagawa K; Takahara M; Ito M; Arai T; Kabe J; Baba H
    Kekkaku; 1994 Sep; 69(9):559-63. PubMed ID: 7967317
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Isoniazid plus rifampicin in the initial treatment of pulmonary tuberculosis.
    Clarke GB; Cuthbert J; Cuthbert RJ; Lees AW
    Br J Dis Chest; 1972 Oct; 66(4):268-71. PubMed ID: 5083434
    [No Abstract]   [Full Text] [Related]  

  • 51. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Short course chemotherapy for tuberculosis in children.
    Padmini R; Srinivasan S; Nalini P; Mahadevan S
    J Trop Pediatr; 1993 Dec; 39(6):361-4. PubMed ID: 8133559
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association.
    Lancet; 1975 Jan; 1(7899):119-24. PubMed ID: 46047
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore.
    Am Rev Respir Dis; 1986 Jul; 134(1):27-33. PubMed ID: 3524334
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical study on the cases in which INH or RFP was discontinued during treatment for pulmonary tuberculosis].
    Harada S; Takamoto M; Ishibashi T; Mohri M; Sato K; Yamagishi F; Sasaki Y; Tanabe K; Sato R; Fujino T; Tano M; Tanizawa M; Sakatani M; Morimoto T; Kawahara S; Hotta N; Shigeto E; Nishimura K; Abe T; Iwanaga T; Oe T; Shimazu K; Ebihara M; Nakagawa S; Kuba M;
    Kekkaku; 2001 May; 76(5):427-36. PubMed ID: 11449698
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic efficacy of rifampin in newly detected pulmonary tuberculosis.
    Jessamine AG; Gale GL; Eidus L
    Can Med Assoc J; 1974 May; 110(9):1033-7. PubMed ID: 4207234
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.
    Grönhagen-Riska C; Hellstrom PE; Fröseth B
    Am Rev Respir Dis; 1978 Sep; 118(3):461-6. PubMed ID: 707874
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rifampin-induced severe thrombocytopenia in a patient with pulmonary tuberculosis.
    Kindelán JM; Serrano I; Jurado R; Villanueva JL; García-Lázaro M; García-Herola A; Torre Cisneros J
    Ann Pharmacother; 1994 Nov; 28(11):1304-5. PubMed ID: 7849351
    [No Abstract]   [Full Text] [Related]  

  • 59. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy.
    Hong Kong Chest Service/British Medical Research Council
    Am Rev Respir Dis; 1989 Dec; 140(6):1618-22. PubMed ID: 2604291
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical effect of rifampicin-ethambutol isoniazid on untreated pulmonary tuberculosis.
    Konno K; Oizumi K; Yamada S; Ogata K; Sato M
    Sci Rep Res Inst Tohoku Univ Med; 1972 Sep; 19(2):68-72. PubMed ID: 4649624
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.